Homepage NewsNews Highlight Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS NANTONG and SUZHOU, China, Nov. 19, 2024 — Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated…Jiaqi HuangNovember 19, 2024
News Highlight Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Jiangsu, China — Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)…ractigenMarch 3, 2023
